NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK shares have decreased by 3.8% and is now trading at $76.25. View which stocks have been mosted impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings data on Wednesday, February, 5th. The company reported $1.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.15 by $0.01. The firm earned $11.87 billion during the quarter, compared to the consensus estimate of $11.71 billion. Merck & Co., Inc. had a return on equity of 49.41% and a net margin of 21.01%. The business's revenue for the quarter was up 7.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.04 earnings per share. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, January 29th. Investors of record on Monday, March 16th will be given a dividend of $0.61 per share on Tuesday, April 7th. This represents a $2.44 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Friday, March 13th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its board has authorized a share repurchase program on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 5.1% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its stock is undervalued.

Merck & Co., Inc. updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share (EPS) guidance of $5.62-5.77 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.54. The company issued revenue guidance of $48.8-50.3 billion, compared to the consensus revenue estimate of $48.65 billion.

16 brokers have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $84.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.00 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

Headlines about MRK stock have been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a news impact score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutMerck & Co., Inc..

Merck & Co., Inc. saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 18,162,700 shares, a decrease of 12.6% from the February 27th total of 20,780,000 shares. Based on an average trading volume of 10,770,000 shares, the short-interest ratio is currently 1.7 days. Approximately 0.7% of the shares of the stock are short sold. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Walt Disney (DIS), Intel (INTC), Cisco Systems (CSCO), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cacti Asset Management LLC (0.03%), Park National Corp OH (0.01%), Neville Rodie & Shaw Inc. (0.01%), Private Asset Management Inc. (0.01%), Woodstock Corp (0.00%) and Cullinan Associates Inc. (0.00%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including First Financial Bank Trust Division, Cacti Asset Management LLC, Park National Corp OH, First National Bank of Mount Dora Trust Investment Services, Cullinan Associates Inc., M&R Capital Management Inc., Pensionfund DSM Netherlands, and Salomon & Ludwin LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Richard R Deluca, and Robert M Davis. View insider buying and selling activity for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Fulton Bank N.A., Pensionfund Sabic, Gantzert Investment Co. LLC ADV, Private Asset Management Inc., Summit Financial Group Inc., Woodstock Corp, Bath Savings Trust Co, and IMS Capital Management. View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $76.25.

Merck & Co., Inc. has a market capitalization of $193.39 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe. View additional information about Merck & Co., Inc..

The official website for Merck & Co., Inc. is http://www.merck.com/.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]